DA-5222-R1

DA-5222-R1 is an investigational pharmaceutical agent being studied as part of a set of related candidate drugs, including DA-5222, DA-5222-R2, and DA-5222-R3. The current clinical focus is on evaluating its pharmacokinetics and safety profiles in healthy adult subjects when administered singly or in combination with other related compounds. The substance is being developed by Dong-A ST and is currently in Phase 1 clinical trials. As of now, the primary indication, detailed mechanism of action, molecular target(s), and route of administration for DA-5222-R1 specifically have not been publicly disclosed. All available studies have focused on pharmacokinetic comparisons rather than therapeutic efficacy or disease-targeting mechanisms[1][3][5][7][9].